Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($1.54), $0.58 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $117.32 million versus the consensus estimate of $117.69 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.